Mereo BioPharma Group Plc (MREO)
0.3066
0.00 (0.00%)
USD |
NASDAQ |
Nov 13, 16:00
0.30
-0.01
(-2.15%)
After-Hours: 19:59
Mereo BioPharma Group Gross Profit Margin (Quarterly) : 49.12% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 49.12% |
| June 30, 2026 | |
| March 31, 2026 |
| Date | Value |
|---|---|
| December 31, 2025 | |
| September 30, 2025 | |
| June 30, 2025 | 14.01% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -- |
| BioNTech SE | 71.11% |
| Silence Therapeutics Plc | 72.27% |
| Autolus Therapeutics Plc | 56.53% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -77.40% |
| Return on Assets | -65.86% |
| Return on Invested Capital | -76.43% |
| Profit Margin (Quarterly) | -732.9% |
| Operating Margin (Quarterly) | -777.3% |
| Return on Net Operating Assets | -1.12K% |